Aardvark Therapeutics Inc. (AARD) has emerged as one of the most closely watched names in the biotech space, with its pipeline targeting obesity and rare genetic disorders. The company's recent clinical updates, strategic alignment with regulators, and strong cash position have set the stage for pivotal milestones in 2026 and beyond.
ARD-101: Expanding Reach in Prader-Willi Syndrome
In October 2025, Aardvark secured FDA alignment to lower the minimum age of eligibility in its Phase 3 HERO trial of ARD-101 for hyperphagia associated with Prader-Willi Syndrome (PWS) from 13 to 10 years. This adjustment broadens the trial's reach and expands the potential patient population. Enrollment has also begun for the HERO Open Label Extension study, with trial sites initiated in Australia.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.